Saturday, August 2, 2025

Latest

Bright Minds Biosciences Looks To Raise $4.0 Million Via Overnight Offering

After several days of intense volatility, Bright Minds Biosciences (CSE: DRUG) is looking to capitalize on the sudden investor interest. The firm has now announced terms for the pricing of its overnight marketed offering of units, following the financing initially being announced on Monday.

The company is looking to raise gross proceeds of roughly $4.0 million, with units being sold at $1.40 per each. Each unit is to contain one common share and one common share purchase warrant, with an exercise price of $1.76. Warrants are to be valid for a period of 24 months from the date of issuance.

A total of 2.9 million units are expected to be sold under the offering, with a 15% over-allotment option also having been granted. The option is valid for a period of 30 days following the closing of the financing.

The financing is being lead by Eight Capital, with HC Wainwright & Co acting as the firms US capital markets advisor.

Proceeds from the financing are to be used for preclinical and clinical development activities, in addition to working capital and general corporate purposes.

The financing follows several days in which the company has seen intense volatility, both on its Canadian as well as its US listing, with the company surpassing $6.00 on the CSE on Thursday, following a close of $1.20 on Wednesday.

Bright Minds Biosciences last traded at $1.75 on the CSE.


FULL DISCLOSURE: Bright Minds Biosciences is a client of Canacom Group, the parent company of The Deep Dive. The company has been compensated to cover Bright Minds Biosciences on The Deep Dive, with The Deep Dive having full editorial control. Not a recommendation to buy or sell. We may buy or sell securities in the company at any time. Always do additional research and consult a professional before purchasing a security.

Video Articles

AngloGold Buys Another Gold Junior! Augusta Gold Acquired For $197 Million

Another Gold Deal! Aris Mining Sells Assets To McFarlane

Royal Gold Goes Big | $3.5 Billion Sandstorm Acquisition

Recommended

Tsunami Warnings Spread As Largest Quake Since 2011 Hits Russia

Northern Superior Intersects 1.75 g/t Gold Over 65.0 Metres At Philibert

Related News

Bright Minds Moves Into Clinical Development Stage Following Positive Toxicity Results

Drug development continues for the Bright Minds Biosciences (CSE: DRUG) lead product. The firm this...

Monday, March 14, 2022, 07:54:42 AM

Bright Minds Bioscience: A Deep Dive

Today we are diving into a firm focused on mental health, whom is also a...

Thursday, December 2, 2021, 01:30:00 PM

Bright Minds Applies For Nasdaq Listing

Bright Minds Biosciences (CSE: DRUG) has an eye for the US big boards. The company...

Wednesday, June 16, 2021, 07:33:59 AM

Bright Minds Biosciences Advances Lead Serotonergic Drug Candidate To Toxicology Studies, Targets Human Trials In 2022

Bright Minds Biosciences (CSE: DRUG) shared today scientific updates regarding its serotonergic drug pipeline. This...

Wednesday, September 22, 2021, 03:24:00 PM

Bright Minds: Eight Capital Assigns $11.50 Price Target To Firm

Last week, Eight Capital launched coverage on a basket of psychedelic companies. This comes after...

Monday, September 20, 2021, 10:09:00 AM